Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers:: a case-control study

被引:77
作者
Narod, Steven A.
Lubinski, Jan
Ghadirian, Parviz
T Lynch, Henry
Moller, Pal
Foulkes, William D.
Rosen, Barry
Kim-Sing, Charmaine
Isaacs, Claudine
Domcheck, Susan
Sun, Ping
机构
[1] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada
[2] Pomeranian Med Univ, Szczecin, Poland
[3] Univ Montreal, Cent Hosp Univ Montreal Hotel Dieu, Epidemiol Res Unit, Montreal, PQ, Canada
[4] Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA
[5] Norwegian Radium Hosp, Dept Canc Genet, Oslo, Norway
[6] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
[7] Univ Hlth Network, Dept Gynecol, Toronto, ON, Canada
[8] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[9] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[10] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[11] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/S1470-2045(06)70624-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Screening mammography is associated with a small dose of radiation to the breast, and women with increased genetic risk might be particularly sensitive to the DNA-damaging effects of ionising radiation. We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers. Methods We identified 1600 cases of breast cancer and 1600 controls without breast cancer who were matched for BRCA mutation, date of birth (within 1 year), and country of residence from an international registry of BRCA1 and BRCA2 mutation carriers. We used a questionnaire to inquire about whether participants had ever had screening mammography, and, if so, the age at which they first had the procedure. Results We found no association between ever having screening mammography and risk of breast cancer (odds ratio [OR] 1.03 [95% CI 0.85-1.25], adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy). The association was much the same for BRCA1 mutation carriers and BRCA2 mutation carriers (1.04 [0.84-1.29] vs 1.06 [0.67-1.66], respectively, adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy). Interpretation These findings do not lend support to the idea that exposure to ionising radiation through routine screening mammography contributes substantially to the burden of breast cancer in BRCA1 and BRCA2 mutation carriers. Prospective studies are needed to confirm the results of this initial report, and, where possible, these studies should assess a more appropriate endpoint of total exposure.
引用
收藏
页码:402 / 406
页数:5
相关论文
共 13 条
[1]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003
[2]  
Friedenson B, 2000, MedGenMed, V2, pE9
[3]   Current perspectives on radiation-induced breast cancer [J].
Goss, PE ;
Sierra, S .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :338-347
[4]   Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990 [J].
Land, CE ;
Tokunaga, M ;
Koyama, K ;
Soda, M ;
Preston, DL ;
Nishimori, I ;
Tokuoka, S .
RADIATION RESEARCH, 2003, 160 (06) :707-717
[5]   Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers [J].
Metcalfe, K ;
Lynch, HT ;
Chadirian, P ;
Tung, N ;
Olivotto, V ;
Warner, E ;
Olopade, OI ;
Eisen, A ;
Weber, B ;
McLennan, J ;
Sun, P ;
Foulkes, WD ;
Narod, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2328-2335
[6]   MORTALITY FROM BREAST-CANCER AFTER IRRADIATION DURING FLUOROSCOPIC EXAMINATIONS IN PATIENTS BEING TREATED FOR TUBERCULOSIS [J].
MILLER, AB ;
HOWE, GR ;
SHERMAN, GJ ;
LINDSAY, JP ;
YAFFE, MJ ;
DINNER, PJ ;
RISCH, HA ;
PRESTON, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (19) :1285-1289
[7]   Guidelines for follow-up of women at high risk for inherited breast cancer:: Consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer [J].
Moller, P ;
Evans, G ;
Haites, N ;
Vasen, H ;
Reis, MM ;
Anderson, E ;
Apold, J ;
Hodgson, S ;
Eccles, D ;
Olsson, H ;
Stoppa-Lyonnet, D ;
Chang-Claude, J ;
Morrison, PJ ;
Bevilacqua, G ;
Heimdal, K ;
Mæhle, L ;
Lalloo, F ;
Gregory, H ;
Preece, P ;
Borg, Å ;
Nevin, NC ;
Caligo, M ;
Steel, CM .
DISEASE MARKERS, 1999, 15 (1-3) :207-211
[8]   Re: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease [J].
Narod, S ;
Lubinski, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (20) :1552-1552
[9]   Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations [J].
Pierce, LJ ;
Strawderman, M ;
Narod, SA ;
Oliviotto, I ;
Eisen, A ;
Dawson, L ;
Gaffney, D ;
Solin, LJ ;
Nixon, A ;
Garber, J ;
Berg, C ;
Isaacs, C ;
Heimann, R ;
Olopade, OI ;
Haffty, B ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3360-3369
[10]   In search of the tumour-suppressor functions of BRCA1 and BRCA2 [J].
Scully, R ;
Livingston, DM .
NATURE, 2000, 408 (6811) :429-432